Jiangtang Decoction for Type 2 Diabetes and NAFLD: Integrative Analysis via Network Pharmacology, Mendelian Randomization, Molecular Docking, and In Vitro Validation.

IF 2
Wenbo Gong, Xueke Lu, Siying Weng
{"title":"Jiangtang Decoction for Type 2 Diabetes and NAFLD: Integrative Analysis <i>via</i> Network Pharmacology, Mendelian Randomization, Molecular Docking, and <i>In Vitro</i> Validation.","authors":"Wenbo Gong, Xueke Lu, Siying Weng","doi":"10.2174/0118715303424915250818045151","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Jiangtang Decoction (JTD) demonstrates notable efficacy in managing Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD). This study aimed to elucidate JTD's causal targets and therapeutic mechanisms by integrating network pharmacology, Summary-data Mendelian Randomization (SMR), and molecular docking, complemented by <i>in vitro</i> validation.</p><p><strong>Materials and methods: </strong>JTD's targets were cross-matched with genes associated with T2DM or NAFLD. SMR and co-localization analyses, utilizing eQTL and pQTL data, identified causal signals for each disease and their shared counterparts. GO/KEGG enrichment analyses were performed on these shared signals. Molecular docking assessed binding interactions. In vitro experiments, including ELISA (Enzyme-linked immunosorbent assay) and lipid staining, evaluated JTD's hypoglycemic/hypolipidemic effects, while PCR/immunofluorescence validated key molecular predictions in High-Glucose and High-Lipid (HGHL)-induced HepG2 cells.</p><p><strong>Results: </strong>Initial network pharmacology identified 1107 JTD targets for T2DM and 1126 for NAFLD. SMR analyses revealed 78 eQTLs and 67 pQTLs for T2DM, and 40 eQTLs and 38 pQTLs for NAFLD. Eight shared causal genetic signals were identified: <i>ADAMTS4, ALDH2, GLO1, CDH1, PDHB, PRKAB1, TCF4,</i> and <i>EP300</i>. <i>In vitro</i>, JTD significantly attenuated hepatic gluconeogenesis and lipid deposition, downregulated IL-1β, and notably restored PRKAB1 expression in HepG2 cells treated with HGHL.</p><p><strong>Discussion: </strong>Enrichment analysis revealed shared processes, including membrane microdomains, oxidoreductase activity, and responses to nutrient and oxygen levels. PRKAB1 exhibited a strong binding affinity with the JTD component Salsalate.</p><p><strong>Conclusion: </strong>This study identified eight genes that are genetically predicted to be causal for the therapeutic effects of JTD on both T2DM and NAFLD, thereby establishing a genetic link between the conditions. These targets and associated pathways illuminate common underlying mechanisms, supporting JTD's potential for integrated treatment strategies and providing a basis for further investigation.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine, metabolic & immune disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715303424915250818045151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Jiangtang Decoction (JTD) demonstrates notable efficacy in managing Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD). This study aimed to elucidate JTD's causal targets and therapeutic mechanisms by integrating network pharmacology, Summary-data Mendelian Randomization (SMR), and molecular docking, complemented by in vitro validation.

Materials and methods: JTD's targets were cross-matched with genes associated with T2DM or NAFLD. SMR and co-localization analyses, utilizing eQTL and pQTL data, identified causal signals for each disease and their shared counterparts. GO/KEGG enrichment analyses were performed on these shared signals. Molecular docking assessed binding interactions. In vitro experiments, including ELISA (Enzyme-linked immunosorbent assay) and lipid staining, evaluated JTD's hypoglycemic/hypolipidemic effects, while PCR/immunofluorescence validated key molecular predictions in High-Glucose and High-Lipid (HGHL)-induced HepG2 cells.

Results: Initial network pharmacology identified 1107 JTD targets for T2DM and 1126 for NAFLD. SMR analyses revealed 78 eQTLs and 67 pQTLs for T2DM, and 40 eQTLs and 38 pQTLs for NAFLD. Eight shared causal genetic signals were identified: ADAMTS4, ALDH2, GLO1, CDH1, PDHB, PRKAB1, TCF4, and EP300. In vitro, JTD significantly attenuated hepatic gluconeogenesis and lipid deposition, downregulated IL-1β, and notably restored PRKAB1 expression in HepG2 cells treated with HGHL.

Discussion: Enrichment analysis revealed shared processes, including membrane microdomains, oxidoreductase activity, and responses to nutrient and oxygen levels. PRKAB1 exhibited a strong binding affinity with the JTD component Salsalate.

Conclusion: This study identified eight genes that are genetically predicted to be causal for the therapeutic effects of JTD on both T2DM and NAFLD, thereby establishing a genetic link between the conditions. These targets and associated pathways illuminate common underlying mechanisms, supporting JTD's potential for integrated treatment strategies and providing a basis for further investigation.

降糖汤治疗2型糖尿病和NAFLD:基于网络药理学、孟德尔随机化、分子对接和体外验证的综合分析。
摘要:降糖汤治疗2型糖尿病(T2DM)和非酒精性脂肪性肝病(NAFLD)疗效显著。本研究旨在通过网络药理学、汇总数据孟德尔随机化(SMR)和分子对接等方法,结合体外验证,阐明JTD的病因靶点和治疗机制。材料和方法:JTD靶点与T2DM或NAFLD相关基因交叉匹配。SMR和共定位分析利用eQTL和pQTL数据,确定了每种疾病及其共同对应疾病的因果信号。对这些共享信号进行GO/KEGG富集分析。分子对接评估结合相互作用。体外实验,包括ELISA(酶联免疫吸附法)和脂质染色,评估了JTD的降糖/降血脂作用,而PCR/免疫荧光验证了高糖高脂(HGHL)诱导的HepG2细胞的关键分子预测。结果:初步网络药理学鉴定出1107个治疗T2DM的JTD靶点和1126个治疗NAFLD的JTD靶点。SMR分析显示T2DM患者有78个eqtl和67个pqtl, NAFLD患者有40个eqtl和38个pqtl。确定了8个共同的因果遗传信号:ADAMTS4、ALDH2、GLO1、CDH1、PDHB、PRKAB1、TCF4和EP300。在体外,JTD显著降低HGHL处理的HepG2细胞的糖异生和脂质沉积,下调IL-1β,显著恢复PRKAB1的表达。讨论:富集分析揭示了共同的过程,包括膜微域、氧化还原酶活性以及对营养和氧水平的反应。PRKAB1与JTD成分Salsalate具有较强的结合亲和力。结论:本研究确定了8个基因,这些基因被预测为JTD对T2DM和NAFLD治疗效果的原因,从而建立了两种疾病之间的遗传联系。这些靶点和相关途径阐明了共同的潜在机制,支持了JTD综合治疗策略的潜力,并为进一步研究提供了基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信